Abstract
The purpose of this publication is to summarize the results of the vaginal erbium:yttrium-aluminum-garnet (Er:YAG) Smooth® laser (VEL) on the vaginal atrophy component of the genitourinary syndrome of menopause (GSM). GSM has two categories of clinical signs related to estrogen deficiency: symptoms of vulvovaginal atrophy (VVA) and urinary symptoms. This symptomatology is chronic, progressive over the years and affects a majority of women concerned by natural menopause but not exclusively: we must also consider the growing number of survivors of gynecological or non-gynecological cancers (breast, cervix, uterus, vagina, anus, etc.). At a time when hormonal treatment of menopause is contested as is the installation of under urethra prosthesis, the innovation provided by the VEL technology has the merit of offering the women concerned an effective therapeutic alternative with the security of a patent. The VEL technology has an original and unique process: acting only by thermal effect and not by ablation on tissue, VEL is a safe solution in terms of side effects and potential complications. Studies have been increasing since 2012 and all demonstrate a significant improvement in the GSM signs and symptoms, as well as an improved sexual life after VEL treatment. Double-blind, placebo-controlled, randomized studies are expected in order to ultimately confirm the safety and effectiveness of VEL.
Author statement
Research funding: None declared.
Conflict of interest: None declared.
Informed consent: Not applicable.
Ethical approval: Not applicable.
References
[1] Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21:1063–8.10.1097/GME.0000000000000329Search in Google Scholar PubMed
[2] Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6:2133–42.10.1111/j.1743-6109.2009.01335.xSearch in Google Scholar PubMed
[3] b-Levine K, Williams R, Hartmann K. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active post-menopausal women. Menopause. 2008;15:661–6.10.1097/gme.0b013e31815a5168Search in Google Scholar PubMed
[4] Palma F, Volpe A, Villa P, Cagnacci A. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. 2016;83:40–4.10.1016/j.maturitas.2015.09.001Search in Google Scholar PubMed
[5] Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61:508–16.10.1097/GRF.0000000000000380Search in Google Scholar PubMed
[6] Ogrinc UB, Senčar S, Lenasi H. Novel minimally invasive laser treatment of urinary incontinence in women. Lasers Surg Med. 2015;47:689–97.10.1002/lsm.22416Search in Google Scholar PubMed PubMed Central
[7] Willhite LA, O’Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy. 2001;21:464–80.10.1592/phco.21.5.464.34486Search in Google Scholar PubMed
[8] Quinn SD, Domoney C. The effects of hormones on urinary incontinence in postmenopausal women. Climacteric. 2009;12:106–13.10.1080/13697130802630083Search in Google Scholar PubMed
[9] Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10:CD001405.10.1002/14651858.CD001405.pub2Search in Google Scholar PubMed
[10] Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results for the Women’s Health Initiative. Randomized control trial. J Am Med Assoc. 2002;228:321–3.Search in Google Scholar
[11] HAS. Commission de la transparence. Réévaluation des traitements hormonaux de la ménopause. Rapport d’évaluation. 2014 : 1– 91.Search in Google Scholar
[12] Crawford SL, Crandall C, Derby CA, El Khoudary SR, Waetjen LE, Fischer M, et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative Study Results. Menopause. 2018;26:588–97.10.1097/GME.0000000000001282Search in Google Scholar PubMed PubMed Central
[13] Peng Q, Juzeniene A, Chen J, Svaasand LO, Warloe T, Giercksky KE, et al. Lasers in medicine. Rep Prog Phys. 2008;71:056701.10.1088/0034-4885/71/5/056701Search in Google Scholar
[14] Vicariotto F, De Seta F, Faoro V, Raichi M. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety. Minerva Ginecol. 2017;69:342–9.10.23736/S0026-4784.17.04072-2Search in Google Scholar
[15] El-Domyati M, Abd-El-Raheem T, Medhat W, Abdel-Wahab H, Anwer MA. Multiple fractional erbium: yttrium-aluminum-garnet laser sessions for upper facial rejuvenation: clinical and histological implications and expectations. J Cosmet Dermatol. 2014;13:30–7.10.1111/jocd.12079Search in Google Scholar
[16] Abrahamse H. Regenerative medicine, stem cells, and low-level laser therapy: future directives. Photomed Laser Surg. 2012;30:681–2.10.1089/pho.2012.9881Search in Google Scholar
[17] Gambacciani M, Levancini M, Russo E, Vacca L, Simoncini T, Cervigni M. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric. 2018;21:148–52.10.1080/13697137.2018.1436538Search in Google Scholar
[18] Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2016;49:160–8.10.1002/lsm.22569Search in Google Scholar
[19] Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17:363–9.10.3109/13697137.2014.899347Search in Google Scholar
[20] Sokol ER, Karram MM. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause. 2016;23:1102–7.10.1097/GME.0000000000000700Search in Google Scholar
[21] Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208.10.1080/009262300278597Search in Google Scholar
[22] Corcos J, Beaulieu S, Donovan J, Naughton M, Gotoh M. Symptom Quality of Life Assessment Committee of the First International Consultation on Incontinence. Quality of life assessment in men and women with urinary incontinence. J Urol. 2002;168:896–905.10.1016/S0022-5347(05)64540-5Search in Google Scholar
[23] Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas. 1995;Suppl. 1:S1–5.10.1016/0378-5122(95)00956-6Search in Google Scholar
[24] Gandhi J, Chen A, Dagur G, Schwamb R, Weissbart SJ, Khan SA. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, aetiology, evaluation and management. Am J Obstet Gynecol. 2016;215:704–11.10.1016/j.ajog.2016.07.045Search in Google Scholar PubMed
[25] Vizintin Z, Mario Rivera M, Fistonić I, Saraçoğlu F, Guimares P, Gaviria J, et al. Novel minimally invasive VSP Er:YAG laser treatments in gynecology. J LAHA. 2012;2012:46–58.Search in Google Scholar
[26] Fistonic I, Findri-Gustek S, Fistonic N. Minimally invasive laser procedure for early stages of stress urinary incontinence (SUI). J LAHA. 2012;2012:67–74.Search in Google Scholar
[27] Gaspar A. Comparaison du nouveau traitement au laser mini-invasif Er: YAG et du traitement hormonal substitutif dans le traitement de l’atrophie vaginale. Climacteric. 2014;17(Suppl 1):48–108, 124.Search in Google Scholar
[28] Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser for genitourinary syndrome of menopause Climacteric. 2015;18:1–7.10.3109/13697137.2015.1071608Search in Google Scholar PubMed
[29] Gambacciani M, Levancini M. Vaginal erbium laser as second generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause. 2017;24(3):316–319.10.1097/GME.0000000000000761Search in Google Scholar PubMed
[30] Gambacciani M, Torelli MG, Martella L, Bracco GL, Casagrande AG, Albertin E, et al. Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. Climacteric. 2015;18(Suppl 1):43–8.10.3109/13697137.2015.1071608Search in Google Scholar
[31] Bojanini JF, Mejía AM. Laser treatment of vaginal atrophy in post-menoause and post-gynecological cancer patients. J LAHA. 2014;1:65–71.Search in Google Scholar
[32] Bojanini JF. Treatment of Genitourinary syndrome of menopause with Erbium:YAG laser: a prospective study of efficacy and safety of the treatment for women after menopause of natural origin and therapy-induced menopause in breast cancer survivors. J LAHA. 2016;1:35–40.Search in Google Scholar
[33] Barber MA, Idoya E. Patient satisfaction with vaginal erbium laser treatment of stress urinary incontinence, vaginal relaxation syndrome and genito-urinary syndrome of menopause. J LAHA. 2016.www.laserandhealth.com.Search in Google Scholar
[34] Lin YH, Hsieh WC, Huang L, Liang CC. Effect of non-ablative laser treatment on overactive bladder symptoms, urinary incontinence and sexual function in women with urodynamic stress incontinence. Taiwan J Obstet Gynecol. 2017;56:815–20.10.1016/j.tjog.2017.10.020Search in Google Scholar PubMed
[35] Gaspar A, Maestri S, Silva J, Brandi H, Luque D, Koron N, et al. Intraurethral Erbium:YAG laser for the management of urinary symptoms of genitourinary syndrome of menopause: a pilot study. Lasers Surg Med. 2018;50(8):802–7.10.1002/lsm.22826Search in Google Scholar PubMed PubMed Central
[36] FDA Warns Against Use of Energy-Based Devices to Perform Vaginal ‘Rejuvenation’ or Vaginal Cosmetic Procedures: FDA Safety Communication. 2018 .Search in Google Scholar
[37] Gambacciani M, Cervigni M. FDA’s Warns Against Use of Energy-Based Devices: The VELA® Safety Communication. Biomed J Sci Tech Res. 2018;12:9102–9104.10.26717/BJSTR.2018.12.002224Search in Google Scholar
[38] Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A, et al. Light and energy-based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med. 2017;49:137–59.10.1002/lsm.22637Search in Google Scholar PubMed PubMed Central
[39] Gambacciani M, Palacios S. Laser therapy for the restoration of vaginal function. Maturities. 2017;99:10–15.10.1016/j.maturitas.2017.01.012Search in Google Scholar PubMed
[40] Gambacciani M, Cervigni M. Erbium laser in gynaecology: aims, aspirations and action points. Climacteric. 2015;18:2–3.10.3109/13697137.2015.1082258Search in Google Scholar PubMed
[41] The American College of Obstetricians and Gynaecologists. Fractional Laser Treatment of Vulvovaginal Atrophy Clearance: Position Statement. 2016.Search in Google Scholar
[42] Blaganje M, Šćepanović D, Žgur L, Verdenik I, Pajk F, Lukanović A. Not ablative Er: YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2018;224:153–8.10.1016/j.ejogrb.2018.03.038Search in Google Scholar PubMed
© 2020 Walter de Gruyter GmbH, Berlin/Boston
